Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Gastroenterology. 2010 Dec;139(6):1927-33. doi: 10.1053/j.gastro.2010.06.061. Epub 2010 Jun 27.
BACKGROUND & AIMS: Germline phosphatase and tensin homolog (PTEN) mutations cause Cowden syndrome (CS), associated with breast and thyroid cancers. Case reports found 35%-85% of CS patients had gastrointestinal (GI) hamartomas. The association of benign and malignant GI neoplasias with CS remains debatable. Our goal is to describe the GI phenotype in a prospective series of PTEN mutation carriers.
Patients who met relaxed International Cowden Consortium criteria (N = 2548) or with 5 or more GI polyps, 1 or more of which was hyperplastic or hamartomatous (N = 397), were prospectively recruited. Germline PTEN mutation/deletion analysis was performed. Of the 2945 patients, 127 (123 of 2548 and 4 of 397, respectively) patients having clear pathogenic PTEN mutations were eligible for this study. Esophagogastroduodenoscopy, colonoscopy, and pathology reports were reviewed. The Fisher 2-tailed exact test, unpaired t tests, and age- and sex-adjusted standardized incidence ratio were calculated.
Of 127 PTEN mutation carriers, 69 underwent 1 or more endoscopies with 64 (93%) having polyps. Of the 64, half had hyperplastic polyps. There were one to innumerable polyps in the colorectum, ileum, duodenum, stomach, and/or esophagus, with 24 subjects having both upper and lower GI polyps. Nine (13%) subjects had colorectal cancer, all younger than the age of 50. The adjusted standardized incidence ratio was 224.1 (95% confidence interval, 109.3-411.3; P < .0001).
PTEN-associated CS should be considered a mixed polyp syndrome, with hyperplastic polyps most prevalent, with a risk of early onset colorectal cancer. Routine colonoscopy should be considered in PTEN-associated CS, especially in the context of hyperplastic and/or adenomatous polyps.
种系磷酸酶和张力蛋白同源物(PTEN)突变导致考登综合征(CS),与乳腺癌和甲状腺癌相关。病例报告发现 35%-85%的 CS 患者存在胃肠道(GI)错构瘤。CS 与良性和恶性 GI 肿瘤之间的关联仍存在争议。我们的目标是描述 PTEN 突变携带者的前瞻性系列 GI 表型。
符合放宽的国际考登综合征联盟标准(N=2548)或有 5 个或更多 GI 息肉,其中 1 个或更多为增生性或错构瘤性(N=397)的患者被前瞻性招募。进行种系 PTEN 突变/缺失分析。在 2945 例患者中,有 127 例(分别为 2548 例中的 123 例和 397 例中的 4 例)患者有明确的致病性 PTEN 突变,符合本研究条件。回顾性分析食管胃十二指肠镜、结肠镜和病理报告。采用 Fisher 2 尾精确检验、独立样本 t 检验和年龄及性别调整的标准化发病比进行计算。
在 127 例 PTEN 突变携带者中,有 69 例行 1 次或多次内镜检查,其中 64 例(93%)有息肉。在 64 例患者中,有一半为增生性息肉。结直肠、回肠、十二指肠、胃和/或食管存在 1 至无数个息肉,24 例患者同时存在上、下 GI 息肉。9 例(13%)患者患有结直肠癌,均早于 50 岁。调整后的标准化发病比为 224.1(95%置信区间,109.3-411.3;P<0.0001)。
PTEN 相关 CS 应被视为混合性息肉综合征,以增生性息肉最为常见,且存在结直肠癌早发风险。PTEN 相关 CS 应考虑行常规结肠镜检查,尤其是在存在增生性和/或腺瘤性息肉的情况下。